J Dermatolog Treat:局部曲安奈德联合富血小板血浆可更好地治疗瘢痕疙瘩

2022-04-15 sunshine MedSci原创

瘢痕疙瘩是皮肤损伤后或自发发生的良性纤维增生,存在于易感人群的瘢痕组织中,通常不会自发恢复,并且在切除后容易复发。它们是由皮肤损伤后不规则的伤口愈合造成的,但有时也会自发发生。

瘢痕疙瘩是皮肤损伤后或自发发生的良性纤维增生,存在于易感人群的瘢痕组织中,通常不会自发恢复,并且在切除后容易复发。它们是由皮肤损伤后不规则的伤口愈合造成的,但有时也会自发发生。瘢痕疙瘩通常有瘙痒和疼痛,大大影响患者的生活质量。局部曲安奈德(TA)是其一线疗法,但通常与副作用或复发有关。富含血小板的血浆(PRP)是一种自体血源产品,在改善伤口愈合和降低瘢痕疙瘩发生率方面具有良好的效果。近日,发表于J Dermatolog Treat的一项随机试验评估和比较了TA和PRP联合皮内注射VS. TA单独注射在治疗瘢痕疙瘩方面的疗效。

研究共纳入40名瘢痕疙瘩患者,随机分为两组(A和B)。两组均接受皮内注射TA(20mg/ml),共4次,间隔3周。A组患者在TA注射后1周接受额外的PRP注射。随访3个月后,通过温哥华疤痕量表(VSS)和口头评分表(VRS)对疼痛和瘙痒进行了评估。

 

结果显示,与基线相比,两组患者的VSS和VRS的所有参数都有明显改善。此外,A组患者在瘢痕高度、色素沉着、柔韧度和总体VSS方面有明显的改善。在患者满意度方面,A组有65%的患者对治疗效果表示满意,35%的患者不满意,而B组有55%的患者表示满意,45%的患者不满意,两组之间无统计学差异。

综上所述,该研究结果表明,在瘢痕疙瘩的治疗中,将PRP与TA结合起来可以产生更好的美容效果,同时降低TA引起的副作用,特别是萎缩和色素减退的发生率。

 

原始出处:

 

El-Sayed Shaaban Hewedy, et al., Combined intralesional triamcinolone acetonide and platelet rich plasma versus intralesional triamcinolone acetonide alone in treatment of keloids. J Dermatolog Treat. 2022 Feb;33(1):150-156. doi: 10.1080/09546634.2020.1730742. 

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811965, encodeId=61d9181196535, content=<a href='/topic/show?id=5ab78905623' target=_blank style='color:#2F92EE;'>#血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89056, encryptionId=5ab78905623, topicName=血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Tue Jun 07 06:42:58 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706085, encodeId=0eca1e060857f, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Thu Dec 22 23:42:58 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967798, encodeId=1aef196e798d4, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jun 20 15:42:58 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796306, encodeId=fac41e963062b, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Jan 28 21:42:58 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337007, encodeId=01dd133e00760, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340371, encodeId=ea5713403e148, content=<a href='/topic/show?id=26bd465e2e3' target=_blank style='color:#2F92EE;'>#富血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46572, encryptionId=26bd465e2e3, topicName=富血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406179, encodeId=5bec14061e953, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811965, encodeId=61d9181196535, content=<a href='/topic/show?id=5ab78905623' target=_blank style='color:#2F92EE;'>#血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89056, encryptionId=5ab78905623, topicName=血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Tue Jun 07 06:42:58 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706085, encodeId=0eca1e060857f, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Thu Dec 22 23:42:58 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967798, encodeId=1aef196e798d4, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jun 20 15:42:58 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796306, encodeId=fac41e963062b, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Jan 28 21:42:58 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337007, encodeId=01dd133e00760, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340371, encodeId=ea5713403e148, content=<a href='/topic/show?id=26bd465e2e3' target=_blank style='color:#2F92EE;'>#富血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46572, encryptionId=26bd465e2e3, topicName=富血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406179, encodeId=5bec14061e953, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
    2022-12-22 gujh
  3. [GetPortalCommentsPageByObjectIdResponse(id=1811965, encodeId=61d9181196535, content=<a href='/topic/show?id=5ab78905623' target=_blank style='color:#2F92EE;'>#血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89056, encryptionId=5ab78905623, topicName=血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Tue Jun 07 06:42:58 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706085, encodeId=0eca1e060857f, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Thu Dec 22 23:42:58 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967798, encodeId=1aef196e798d4, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jun 20 15:42:58 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796306, encodeId=fac41e963062b, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Jan 28 21:42:58 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337007, encodeId=01dd133e00760, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340371, encodeId=ea5713403e148, content=<a href='/topic/show?id=26bd465e2e3' target=_blank style='color:#2F92EE;'>#富血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46572, encryptionId=26bd465e2e3, topicName=富血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406179, encodeId=5bec14061e953, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1811965, encodeId=61d9181196535, content=<a href='/topic/show?id=5ab78905623' target=_blank style='color:#2F92EE;'>#血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89056, encryptionId=5ab78905623, topicName=血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Tue Jun 07 06:42:58 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706085, encodeId=0eca1e060857f, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Thu Dec 22 23:42:58 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967798, encodeId=1aef196e798d4, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jun 20 15:42:58 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796306, encodeId=fac41e963062b, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Jan 28 21:42:58 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337007, encodeId=01dd133e00760, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340371, encodeId=ea5713403e148, content=<a href='/topic/show?id=26bd465e2e3' target=_blank style='color:#2F92EE;'>#富血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46572, encryptionId=26bd465e2e3, topicName=富血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406179, encodeId=5bec14061e953, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1811965, encodeId=61d9181196535, content=<a href='/topic/show?id=5ab78905623' target=_blank style='color:#2F92EE;'>#血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89056, encryptionId=5ab78905623, topicName=血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Tue Jun 07 06:42:58 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706085, encodeId=0eca1e060857f, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Thu Dec 22 23:42:58 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967798, encodeId=1aef196e798d4, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jun 20 15:42:58 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796306, encodeId=fac41e963062b, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Jan 28 21:42:58 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337007, encodeId=01dd133e00760, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340371, encodeId=ea5713403e148, content=<a href='/topic/show?id=26bd465e2e3' target=_blank style='color:#2F92EE;'>#富血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46572, encryptionId=26bd465e2e3, topicName=富血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406179, encodeId=5bec14061e953, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1811965, encodeId=61d9181196535, content=<a href='/topic/show?id=5ab78905623' target=_blank style='color:#2F92EE;'>#血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89056, encryptionId=5ab78905623, topicName=血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Tue Jun 07 06:42:58 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706085, encodeId=0eca1e060857f, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Thu Dec 22 23:42:58 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967798, encodeId=1aef196e798d4, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jun 20 15:42:58 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796306, encodeId=fac41e963062b, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Jan 28 21:42:58 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337007, encodeId=01dd133e00760, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340371, encodeId=ea5713403e148, content=<a href='/topic/show?id=26bd465e2e3' target=_blank style='color:#2F92EE;'>#富血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46572, encryptionId=26bd465e2e3, topicName=富血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406179, encodeId=5bec14061e953, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1811965, encodeId=61d9181196535, content=<a href='/topic/show?id=5ab78905623' target=_blank style='color:#2F92EE;'>#血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89056, encryptionId=5ab78905623, topicName=血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Tue Jun 07 06:42:58 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706085, encodeId=0eca1e060857f, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Thu Dec 22 23:42:58 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967798, encodeId=1aef196e798d4, content=<a href='/topic/show?id=c905e1228d9' target=_blank style='color:#2F92EE;'>#瘢痕疙瘩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71228, encryptionId=c905e1228d9, topicName=瘢痕疙瘩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jun 20 15:42:58 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796306, encodeId=fac41e963062b, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Jan 28 21:42:58 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337007, encodeId=01dd133e00760, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340371, encodeId=ea5713403e148, content=<a href='/topic/show?id=26bd465e2e3' target=_blank style='color:#2F92EE;'>#富血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46572, encryptionId=26bd465e2e3, topicName=富血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406179, encodeId=5bec14061e953, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Apr 13 04:42:58 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
    2022-04-13 chg122

相关威廉亚洲官网

Rom J Ophthalmol:用筋膜下注射曲安奈德治疗继发于旋转萎缩的囊样黄斑水肿

土耳其Zilan医院眼科的Alparslan等人近日在Rom J Ophthalmol杂志上发表了一篇文章,作者报告了一例继发于旋转萎缩的黄斑囊样水肿的儿童病例。

Am J Clin Dermatol:每日一次的曲安奈德0.05%乳液对中重度痤疮患者生活质量的影响

在两项针对中度至重度痤疮患者的III期临床试验中(NCT02932306,NCT02965456),相对于载体乳液,0.05%曲安奈德乳液减少了炎症和非炎症性病变,较小可能刺激皮肤。

J Dermatolog Treat:曲安奈德制剂可有效治疗痤疮

几乎所有人都在青春期或年轻时的某个阶段饱受痤疮的困扰,但是目前在治疗寻常性痤疮方面,尚缺乏耐受性良好的外用治疗方法。

Ophthalmologica:玻璃体腔内注射曲安奈德与白内障手术联合治疗效果评估

日本东京女子医科大学东京医学中心眼科的Nunome T近日在Ophthalmologica发表了一篇文章,他们在抗血管内皮生长因子(抗VEGF)治疗的糖尿病性黄斑水肿(DME)患者中,评估玻璃体内注射曲安奈德注射液(IVTA)联合白内障手术治疗方法的有效性。

JAMA:注射曲安奈德可造成膝骨关节炎患者的软骨体积损失?

2017年5月,发表在《JAMA》的一项由美国科学家进行的随机临床试验,考察了关节腔内注射曲安奈德vs生理盐水对膝骨关节炎患者的膝关节软骨体积和疼痛的影响。

曲安奈德联合抗VEGF药物球内注射治疗脉络膜结核瘤1例

患者男性,18岁。因左眼视力下降伴视物变形1个月就诊,